1. Background {#sec1}
=============

Malignancy and aortic aneurysms are common diseases, particularly among aging population. Nearly three quarters of malignant cases are diagnosed in people aged 60 years and over \[[@B1]\]. Abdominal aortic aneurysms occur in about 7-8% of male population over the age of 65 years and is rare under the age of 55 years \[[@B2]\]. The coexistence of malignant disease and aortic aneurysm presents a real management challenge, especially in establishing the therapeutic priorities and the ideal treatment approach. This study aims at reviewing the diagnosis modalities and treatment options and the changes that have taken place with the advances in the management of both cancer and aortic aneurysms, particularly with the development of minimally invasive procedures.

2. Design and Methods {#sec2}
=====================

The MEDLINE and HIGHWIRE databases were searched using the terms ("neoplasms"\[MeSH Terms\] or "neoplasms"\[All Fields\] or "cancer"\[All Fields\]) and ("aortic aneurysm"\[MeSH Terms\] or ("aortic"\[All Fields\]) and ("aneurysm"\[All Fields\] or "aortic aneurysm"\[All Fields\]). All abstracts from the English language articles and foreign language articles were examined by a single reviewer. Papers detailing relevant data were assessed for quality and relevance independently by two separate reviewers. All case series, review articles, and references of such articles were searched for additional relevant papers. Papers that outlined their relevant experience and outcome of their approach sufficiently to allow comparison were included; articles that failed to detail the effect of treatment approach on outcome were excluded. A total of 139 articles were identified. Of these 139 papers, 75 were case series, 57 were case reports, and 5 were discussion papers on various aspects of aortic aneurysm and cancer and all were included in this paper.

3. Incidence {#sec3}
============

Although the true incidence of concomitant malignancy and aortic aneurysm is difficult to establish, most centers report a low incidence of intra-abdominal malignancy in patients with abdominal aortic aneurysm. Malignancies were found in 4% of AAA cases in one of the earlier reviews covering a period of 22 years ([Table 1](#tab1){ref-type="table"}). Some authors report a much higher incidence rate, with up to 14% of AAA cases associated with malignancy in one series published in Japan ([Table 1](#tab1){ref-type="table"}). Based on the natural history of AAA simulated to match the age-specific prevalence rate for male subjects, AAA was estimated to coincidentally occur in 8.3% of patients with intra-abdominal malignancy. This includes colorectal cancers detected using virtual colonoscopy \[[@B3]\].

4. Aetiology {#sec4}
============

Aortic aneurysms are due to degenerative changes in the aortic wall. Some reports have found an association between the presence of cancer and mycotic aortic aneurysm. For instance, Mycobacterium bovis was found in the wall of a ruptured abdominal aortic and femoral artery aneurysm following intravesical bacillus Calmette-Guérin (BCG) therapy for bladder cancer \[[@B4], [@B5]\]. Listeria monocytogenes infection was also found in the wall of a resected thoracic aneurysm two months before advanced rectal cancer was diagnosed. The authors believed that the rectal cancer predisposed the patient to the development of an arterial infection associated with L. monocytogenes \[[@B6]\]. Clostridium septicum mycotic aortic aneurysm has been reported simultaneously with colon cancer \[[@B7]\]. The presence of infection influences the natural history and management. These findings do not establish a causal association but do raise the possibility of an infective aetiology in a very small number of aneurysms.

5. Clinical Presentation {#sec5}
========================

Most synchronous abdominal aortic aneurysms and cancers are found incidentally during the investigation or treatment stages. Nevertheless, suspicion of the presence of cancer has been occasionally raised during the workup for aortic aneurysm and vice verse. [Table 2](#tab2){ref-type="table"} details some examples of such cases.

6. Investigations {#sec6}
=================

Computerised tomography (CT) scan is the most common investigation reported to detect the presence of abdominal aortic aneurysms concomitantly with visceral malignancies and vice verse. Occasionally, malignancies are detected incidentally during laparotomy \[[@B8]\] or following an endoscopic procedure such as bronchoscopy \[[@B9]\], upper gastrointestinal \[[@B10]\], or lower gastrointestinal \[[@B11]\] endoscopy. Virtual colonography \[[@B3], [@B12], [@B13]\] or whole-body CT scanning \[[@B14]\] was recommended by some as a more cost-effective strategy to use in population-based screening programmes but not widely accepted.

7. Management {#sec7}
=============

There is no consensus on the best management approach for patients with simultaneous aortic aneurysm and malignancy. Several strategies have been considered, namely, to repair the aneurysm first and treat the malignancy later, to resect the malignancy first and repair the aneurysm later, to undertake both procedures simultaneously, and in some cases to treat the malignancy and manage the aneurysm conservatively.

Aortic aneurysm repair is a prophylactic procedure and is worthwhile where the lifetime risk of rupture exceeds the risk from treatment. The prognosis of cancer is therefore central to the decision making process.

The perceived increase risk of aortic aneurysm rupture following cancer surgery, the significant delay in the treatment of cancer if aneurysm is treated first, and the risk of graft infection are the other important considerations in the management of concomitant aortic aneurysm and cancer.

[Table 3](#tab3){ref-type="table"} summarizes the different approaches used in the treatment of different patient groups in case series and their outcome.

8. Discussion {#sec8}
=============

The treatment of AAA with coexisting malignancy represents a challenging issue to the cancer and vascular specialists in terms of priority, timing, and expected outcome. Most published papers consist of fairly small case series. Prospective randomized controlled trials with adequate statistical power have understandably not been done in this area. In the absence of such level of evidence, one has to combine the best available evidence with a sound clinical judgment applied on each individual case within a multidisciplinary setting.

The management challenge was reflected on a survey of 46 general and vascular professors in the USA in 1985 who gave their responses as to which condition should receive priority of treatment \[[@B15]\]. Excision of the carcinoma first was favored by about a third of them, repair of the aneurysm first was favored by another third, and the remaining third stated that they would withhold a decision until laparotomy was performed. The survey was undertaken in the mid-eighties and a similar survey in the current era would probably show different opinions, especially with the introduction of endovascular and laparoscopic approaches and the availability of advanced preoperative staging techniques and adjuvant therapy.

There is some evidence that abdominal surgery increases the risk of aneurysm rupture, especially when the AAA diameter is over 5 cm. Baxter et al. \[[@B16]\] from the Mayo Clinic reported two AAA ruptures in the immediate postoperative period following 20 CRC (colorectal cancer) excisions (10% incidence rate). A similar phenomenon was noted by Lin et al. from the Michael E. DeBakey Departement of Surgery, with AAA rupture incidence rate of 6% following CRC resection \[[@B17]\]. Swanson et al. \[[@B18]\] noted this complication in ten previously asymptomatic patients with aneurysms within 36 days of a prior laparotomy, with a mean AAA diameter of 9.1 cm. On the other hand, Durham et al. \[[@B19]\] prospectively studied 33 patients (29 men, 4 women) with a known abdominal aortic aneurysm who underwent 45 operations. The estimated risk of rupture was 3% of all patients undergoing major operation in this study. It was hypothesized that a reduction in the collagen contents of aortic wall following trauma may predispose the aortic aneurysm to rupture, through a mechanism mediated by collagenase and protease activation \[[@B18], [@B20]\].

The effect of delayed cancer treatment on the long-term outcome remains unclear. Ideally, any delay in cancer management should be avoided. A few months delay before initiating treatment of oesophageal cancer, for example, would have an impact on the stage of the cancer, and thereby on the patients\' prognosis \[[@B21]\]. Nevertheless, disease stage at the time of diagnosis is probably the most important influence on survival, and some delay in treatment may not strongly be associated with variation in survival \[[@B22]\]. Delays occurring due to poor organization or the magnitude of the first operation requiring prolonged recovery before the second operation took place, need to be tackled as modern practice allows.

Authors from many large centers (the Mayo Clinic, USA \[[@B11]\], The Cleveland Clinic Foundation, USA \[[@B31]\], the University of Naples Federico II and University of Turin, Italy \[[@B27], [@B34]\], the Michael E. DeBakey Department of Surgery, USA \[[@B33]\], the Keio University School of Medicine, Japan \[[@B32]\], the Imperial College London, UK \[[@B36]\], the Concord Repatriation General Hospital, Australia \[[@B23]\], and others \[[@B6], [@B35]\]) agree that the most life-threatening (or symptomatic) lesion should be addressed first. Large abdominal aortic aneurysms, obstructing colonic cancers, or bleeding gastric cancers, for example, should be treated first where possible. The treatment modality may be a minimally invasive procedure (e.g. stenting for obstructing CRC) that can allow optimization and a better planned therapy \[[@B27]\].

A one-stage operation to repair the aortic aneurysm and resect the malignancy has the advantage of avoiding a second major abdominal operation, avoiding the potential risk of ruptured aneurysm following the cancer resection stage, avoiding the potential delay in cancer treatment if the aortic aneurysm was addressed first, and avoiding the potential difficulty in dealing with adhesions resulting from an earlier laparotomy \[[@B23]--[@B17]\]. Most studies have not shown any significant increase in the risk of graft infection following a one-staged operation (see [Table 3](#tab3){ref-type="table"}, \[[@B33], [@B32], [@B24], [@B30], [@B31], [@B23], [@B17]--[@B34], [@B35]\]). Nevertheless, few reports have documented a possible correlation between graft infection and simultaneous open abdominal surgery \[[@B24], [@B36], [@B37]\]. The cumulative morbidity and mortality were significantly higher in one-staged operations when compared to two-staged operations in some reports (Lin et al. \[[@B17]\]), and the one-staged option as a primary approach was unfavorable by some authors accordingly (Lin et al. \[[@B17]\] and Hafez et al. \[[@B23]\]). Combined operation in cases where both lesions pose a life-threatening condition (e.g. large aneurysm with advanced obstructing malignancy) is supported by most authors, providing a very high attention to details in place (thoughtful antibiotic coverage and possible irrigation of operative field with antibiotics \[[@B26]\], usage of antibiotic-bound grafts \[[@B11]\], good-risk patient selection, verified good colonic blood supply to avoid necrosis, possible use of omental wrap around the vascular graft \[[@B16], [@B26], [@B35]\], possible spray of fibrin glue around anastomosis \[[@B26]\], using extra-anatomic bypass instead of a grafted aorta \[[@B26]\], etc.) (Baxter et al. \[[@B16]\], Lin et al. \[[@B17]\], Robinson et al. \[[@B11]\], Suffat et al. \[[@B25]\], and Shalhoub et al. \[[@B27]\]). Some authors, however, remain in favor of a combined operation as a primary management approach to synchronous lesions \[[@B33], [@B32], [@B23], [@B26], [@B25]\], especially for fairly clean operations such as gastric \[[@B32], [@B25]\] or urological cancers \[[@B23], [@B34]\].

Staged operation (repair of aortic aneurysm first or resection of malignancy first) has the theoretical advantage of avoiding major longer operation and avoiding the risk of cross-contamination and consequent devastating graft infection. Nevertheless, many reports have shown a significant time delay before the second operation (especially when malignancy is treated first) \[[@B33], [@B16], [@B17], [@B28], [@B39], [@B38]\], a high incidence of catastrophic sequelae (ruptured aortic aneurysm in the case of treating the malignancy first) \[[@B16], [@B11], [@B24], [@B17]\], or a significant decrease in the long-term survival, especially when one pathology was treated eventually \[[@B23], [@B39], [@B35]\]. Despite these unfavourable 'side effects\' of staged operations, this option (malignancy-first or aorta-first approach) remains the preference for some authors \[[@B29], [@B28], [@B27]\]. Few questions such as the impact of aneurysm repair in staged procedure on the timing of adjuvant therapy and the effect of radiotherapy on the EVAR stent need further well-controlled studies in the future.

Endovascular aortic repair (EVAR) in the treatment of concomitant malignancy has attracted much attention more recently \[[@B24], [@B23], [@B17], [@B25], [@B27], [@B39]\]. As EVAR does not involve a laparotomy, patients recover quickly and in most cases would be able to undergo the cancer surgery within a couple of weeks if required. Drury and colleagues \[[@B40]\] performed a systematic review and meta-analysis of randomized controlled trials on EVAR and showed a persistent reduction in 30-day mortality (1.6 versus 4.7%) and lower incidence of major complications (including cardiac, respiratory, and renal) after EVAR procedures when compared to open procedures \[[@B40]\]. In line with these results, most authors dealing with synchronous AAA and malignancy have found a persistent decrease of the interval period between repairing the aortic aneurysm using EVAR and performing the malignancy operation in the two-staged approach \[[@B24], [@B17], [@B27]\], a persistent reduction in operative morbidity and mortality \[[@B24], [@B17]\] that was sustained up to 3-4 years of followup \[[@B24], [@B17]\], and a significant reduction in length of hospital stay (unless endoleak has to be ruled out \[[@B27], [@B39]\]), and in the intraoperative blood loss \[[@B24], [@B17], [@B27], [@B41]\]. Colonic ischaemia is rare after an EVAR procedure. However, recent prior colonic surgery may predispose patients to such a complication as reported in 2 patients who had right hemicolectomy (with confirmed patent IMA) followed by a staged EVAR (18% incidence rate) in one report \[[@B17]\]. Lin and colleagues recommended using additional preoperative imaging to confirm the presence of SMA/IMA collateral flow before embarking on such staged operations \[[@B17], [@B39]\]. Endovascular aneurysm repair, where possible, followed by malignancy operation has become the initial preferred treatment choice in some centers \[[@B23], [@B17], [@B25], [@B39]\]. The risk of vascular graft infection is also likely to be less with an EVAR procedure, as there is no risk of direct contamination during the resection of abdominal malignancy.

Patients with advanced/end-stage malignancy and large aortic aneurysm require sound ethical consideration and balanced clinical judgment \[[@B29], [@B33], [@B28], [@B35]\]. A good understanding of the expected outcome in each specific cancer type, as well as the presence of other comorbidities (age, physiologic well-being, etc.) is essential for a proper decision making within a multidisciplinary team approach. Aneurysm repair would be considered inappropriate if curative resection is not feasible, even if the EVAR procedure can be carried out with minimum morbidity. The EVAR II trial is particularly helpful in this context. Patients who were deemed unfit for open aortic aneurysm repair were randomly allocated to best medical therapy alone or EVAR and best medical therapy. The trial was weakened by a significant number of patients that crossed over to undergo aneurysm repair. Nevertheless, the trial showed that patients with significant comorbidity do not show any survival benefits with AAA repair \[[@B42]\]. These data can be relevant to cancer patients with poor prognosis who are, on a similar basis, unlikely to benefit from AAA repair.

The need for adjuvant therapy for cancer treatment is another factor to consider when planning for a staged or simultaneous operation \[[@B27]\]. Lauro et al. have raised concerns regarding chemotherapy treatment (associated with aggressive hydration and corticosteroids) in patients known to have AAA \> 6 cm. Such treatment may result in enlargement of major arteries and may increase the risk of rupture \[[@B20]\]. There are no documented reports of chemotherapy-related aneurysm rupture so far. Chemotherapy administered to patients before or after EVAR had no consequences in some reports \[[@B27]\]. Data on the risk of aneurysm rupture due to chemotherapy is limited and should not be an important consideration in management decision. It would be entirely reasonable to await the response of chemotherapy and get a better estimate of prognosis before undertaking the repair of aneurysm.

The extent of nodal dissection has significant effect on the overall cancer prognosis, including the need for adjuvant therapy. No technical difficulties or specific limitation have been reported in this respect, including performing a D2 lymphadenectomy in gastric cancer \[[@B32]\] or total mesorectal excision and full node dissection in rectal cancer \[[@B39]\]. However, a one-staged operation appears to be correlated with more D2 dissection and less total gastrectomy rate when compared to staged operations in some series \[[@B35]\]. The effect of paraaortic tissue dissection during open aortic aneurysm repair on the cancer staging or outcome (in terms of cancer dissemination or effect on chemoradiotherapy) or the effect of finding metastatic malignancy following the first stage of treatment (malignancy-first approach) on the cost-effectiveness of aortic-repair stage \[[@B27]\] remains to be investigated further.

Treatment priorities and patients\' best interest should be considered when one of the two lesions is found incidentally intraoperatively \[[@B39]\]. Treating the most immediate life-threatening condition and a two-staged operation might be a sensible option in such circumstances. It should be possible to diagnose aneurysms on CT in most patients preoperatively but malignancy may be occasionally overlooked on the preoperative CT scan for aneurysms. The increasing use of EVAR techniques means that most of these lesions will be detected on preoperative or postoperative surveillance scans and can be treated in the stages.

The management decision for concomitant malignancy and aortic aneurysm needs to be made for each individual case based upon the best estimates of risks of aneurysm rupture, operative risks, prognosis of malignancy, and patient preference. There are multiple variables and it will be difficult to obtain high-level evidence for these patients. It is therefore essential to discuss such cases in a multidisciplinary setting to achieve a consensus opinion before gaining approval from the patient on one option or another.

###### 

Prevalence of aortic aneurysm and concomitant malignancy.

  Source                                 AAA                                                      Malignant disease             Colorectal cancer                                      Observation period, yr
  -------------------------------------- -------------------------------------------------------- ----------------------------- ------------------------------------------------------ ------------------------
  Szilagyi et al.,1967 \[[@B43]\]\*      803                                                      31 (3.9)                      9 (1.2)                                                22
  Nora et al., 1989 \[[@B44]\]           3500                                                     NA (the emphasis is on CRC)   17 (0.5) (those underwent operations for Ca and AAA)   12
  Morris and Colquitt, 1988 \[[@B29]\]   158 (looking at all but with histologically proven ca)   20 (12.7)                     6 (3.8)                                                12
  Tennant 1990 \[[@B45]\]                247                                                      4 (1.6)                       0                                                      5
  Oshodi et al., 2000 \[[@B33]\]         676                                                      8 (1.2)                       4 (0.6)                                                20
  Tsuji et al., 1999 \[[@B46]\]          162                                                      4 (2.5)                       1 (0.6)                                                10
  Matsumoto et al., 2002 \[[@B47]\]      260                                                      29 (11.2)                     16 (6.2)                                               14
  Baxter et al., 2002 \[[@B16]\]         10 872                                                   NA                            83 (0.8)                                               15
  Yamamoto et al. \[[@B48]\]             408 (using FOB to detect CRC)                            ---                           6 (1.5%) with cancer and 16 (3.9) with polyps          ---
  Onohara et al. \[[@B32]\]              112                                                      16 (14%)                      ---                                                    ---

\*This study was performed in the pre CT/Duplex era and therefore unlikely to detect cancer. AAA: abdominal aortic aneurysm. CRC: colorectal cancer. NA: not applicable. FOB: faecal occult blood.

###### 

Examples of clinical presentation of aortic aneurysm and/or associated malignancy.

  Source                          Setting                          No. of cases   Mode of presentation\*
  ------------------------------- -------------------------------- -------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Upchurch and Clair \[[@B49]\]   Cancer in aortic aneurysm case   1 case         Ruptured AAA associated with aortocaval fistula was complicated by C. Septicum sepsis. CRC was suspected and found on investigations.
  Tsui, et al. \[[@B50]\]         Cancer in aortic aneurysm case   1 case         Haemoptysis in TAA was initially related to the aneurysm. Lung cancer was suspected thereafter and found.
  Van Doorn et al. \[[@B9]\]      Aortic aneurysm in cancer case   1 case         Sepsis and widened mediastinum developed after CRC operation. Thoracic aneurysm was suspected and found.
  Mohamed et al. \[[@B7]\]        Aortic aneurysm in cancer case   1 case         CT scan in a patient with sepsis and abdominal pain revealed ruptured aorta with pseudoaneurysm. Repeated CT scan in another centre found CRC in pelvis.
  Sebastian et al. \[[@B10]\]     Cancer in Aortic aneurysm case   1 case         Unsettled dysphagia in TAA was investigated further. Oesophageal cancer was found.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference (first author)       Type of cancer                  No. of cases                                                Group          Approach                                                           AAA rupture rate (period)                                                             Interval between AA repair and cancer treatment   Delay in cancer treatment   Cancer outcome                                      Graft complication rate                    \% mortality rate (mode)
  ------------------------------ ------------------------------- ----------------------------------------------------------- -------------- ------------------------------------------------------------------ ------------------------------------------------------------------------------------- ------------------------------------------------- --------------------------- --------------------------------------------------- ------------------------------------------ ----------------------------
                                 CRC                             83 (of 435 AAA pts over 8 yrs)                              One: 44pts     CRC treated first. AAA average size 3.8 cm                         1/44 ruptured (7yrs later) 1/44 died of sepsis following repair of AAA (1 yr later)                                                     4 days                      13% recurrence                                                                                 4.5% (30 d)

  Baxter et al. \[[@B16]\]                                                                                                   Two: 20pts     CRC treated first. AAA average size 5.4 cm                         2/20 (10%) had rAAA postoperatively. 1 died                                                                                             8 days                      33% recurrence                                                                                 10% (30 d)

                                                                                                                             Three: 12pts   AAA and CRC treated simultaneously. AAA average size 6.4 cm        0%                                                                                                                                      15 days                     17% recurrence                                                                                 14% (30 d)

                                                                                                                             Four: 7pts     AAA treated first. AAA average size 6 cm                           0%                                                                                                                                      122 days                    9% recurrence                                                                                  8% (30 d)

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                 Different types\                25                                                          One: 11        EVAR performed first. AAA average size 5.9 cm                                                                                                            6.5 days (average)                                                                                                                2/11 graft occlusion---0/11 infection      0% (periop)
                                 (urinary tract, GI, and lung)                                                                                                                                                                                                                                                                                                                                                                                                                    

  Porcellini et al. \[[@B24]\]                                                                                               Two: 7         Open surgery performed first. AAA average size 6.8 cm              0                                                                                     34 days                                                                       3 died of mets (11, 15, and 39 mo)                  1/14 graft infection                       3/14 died after AAA repair

                                                                                                                             Three: 6       One-stage operation                                                0                                                                                     0                                                                             1 died of mets (15 mo)                                                                         0%

                                                                                                                             Four: 1        Cancer first                                                       1                                                                                     82 d                                                                          alive (55 mo)                                       0                                          0%

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                 CRC                             7                                                           Open: 5        AAA and CRC treated simultaneously. AAA average size?              0                                                                                                                                       NS                          NS                                                  0%                                         

  Herald et al. \[[@B30]\]                                                                                                   EVAR: 1        AAA and CRC treated simultaneously. AAA average size NS            0                                                                                     0                                                 NS                          Alive (12 months)                                   0%                                         

                                                                                                                             EVAR: 1        AAA before the CRC. AAA average size NS                            0                                                                                     14                                                NS                          Alive (6 months)                                    0%                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Chai et al. \[[@B51]\]         CRC                             2                                                                          EVAR followed by CRC resection                                     0                                                                                     7                                                 NS                          Alive (12 months)                                   100% (graft occlusion). Case report type   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Sheen et al. \[[@B31]\]        Pancreas                        1                                                                          EVAR followed by pancreatectomy                                    0                                                                                     9                                                 NS                          Alive (1 month)                                     0%                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                 Renal                           27                                                          11             One stage                                                          0                                                                                     0                                                                             80% survival                                        0 (57months)                               

  Hafez et al. \[[@B23]\]                                                                                                    13             AAA first                                                          0                                                                                     ?                                                                             35% survival                                        0 (57months)                               

                                                                                                                             3              Renal malignancy first                                             0                                                                                     ?                                                                             80% survival                                        0 (57months)                               

                                                                                                                                            different grouping                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Matsumoto\                     Gastric and\                    25 (out of 186 AAA repairs) - high risk pts only included   Group 1: 14    One-stage operation                                                0                                                                                                                                       NA                          2 died of renal failure (10 mo) or mets (2yrs)      NA                                         0\
  et al. \[[@B47], [@B26]\]      colorectal cancer                                                                                                                                                                                                                                                                                                                                                                                                                                (Periop)

                                                                                                                             Group 2: 11    Two-stage operation                                                0                                                                                                                                       NA                          1 died of Mi (3 mo)                                 NA                                         0\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  (Periop)

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                 CRC                             108                                                         Group 1: 46    CRC treated first. AAA second: group A: 35 open/group B: 11 EVAR                                                                                         A: 42 d/B: 35                                                                                                                     2/11 (Group B) had sigmoid ischaemia       

  Lin et al. \[[@B17]\]                                                                                                      Group 2: 38    AAA first: Group C: 26 open/Group D: 12 EVAR                                                                                                                                                               C: 115/D: 12                Significant periop morbidity/mortality in Group C                                              

                                                                                                                             Group 3: 8     Combined                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                 All (mostly CRC)                7 (127 AAAs)                                                Group 1: 3     One stage                                                                                                                                                                                                                                                                                  0%                                         

  Suffat et al. \[[@B25]\]                                                                                                   Group 2: 1     Two stage (?)                                                                                                                                                                                                                                                                              0%                                         

                                                                                                                             Group 3: 3     EVAR                                                                                                                                                                                                       Few days                                                                        0%                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                 gastric                         6 (222 AAAs)                                                Group 1: 3     CRC first (advanced cancer)                                                                                                                                                                                                            71% alive at 4 yrs                                                                             

  Komori et al. \[[@B28]\]                                                                                                   Grorp 2: 1     AAA first (\>6 cm)                                                                                                                                                                                                                                                                                                                    

                                                                                                                             Group 3: 2     One stage                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                 CRC                             13                                                          Group 1: 10    CRC first; Open AAA (3) or EVAR (7) second                         0                                                                                                                                                                                                                       0                                          

  Shalhoub et al. \[[@B27]\]                                                                                                 Group 2: 2     AAA first (diameter 7&8 cm)                                        0                                                                                                                                                                                                                       0                                          

                                                                                                                             Group 3: 1                                                                        0                                                                                                                                                                                                                       0                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Oshodi et al. \[[@B33]\]       All                             56 (676)                                                                   One-stage open surgery                                             3 deaths/7 early reoperation                                                          0                                                                                                                                 0                                          0\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  (Periop)

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Galt et al. \[[@B34]\]         renal                           10                                                                         One stage                                                          0                                                                                     0                                                 NS                          1 died from mets                                    0                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Veraldi et al. \[[@B39]\]      CRC                             14                                                          Group 1: 9     One stage                                                          0                                                                                     0                                                                             NA                                                  0 (up to 5yrs)                             0\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  (Periop)

                                                                                                                             Group 2: 7     Two stage                                                          0                                                                                     31 d                                                                          NA                                                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*AAA: abdominal aortic aneurysm. CRC: colorectal cancer. GI: Gastrointestinal. NS: not specified. NA: not applicable/not provided. EVAR: endovascular aneurysm repair.
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